Pharmacologic treatment of heroin-dependent patients

Annals of Internal Medicine

Volumn 133, Issue 1, 2000, Pages 40-54

  O'Connor, Patrick G ^a   Fiellin, David A ^a   Hudson, Barbara ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 208025 ^*

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CLONIDINE; LEVACETYLMETHADOL; LOFEXIDINE; METHADONE; NALTREXONE;

DATA BASE; DRUG DETOXIFICATION; DRUG EFFICACY; HEROIN DEPENDENCE; METHADONE TREATMENT; PRIORITY JOURNAL; RELAPSE; REVIEW; SUBSTANCE ABUSE; TREATMENT PLANNING; WITHDRAWAL SYNDROME;

EID: 0034604239     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-1-200007040-00008     Document Type: Review

References (140)

1. Harwood HJ, Fountain D, Livermore C. The Economic Costs of Alcohol and Drug Abuse in the United States, 1992. The Lewin Group. Rockville, MD: National Institute on Drug Abuse; 1998.
2. Schorling JB, Buchsbaum D. Screening for alcohol and drug abuse. Med Clin North Am. 1997;81:845-65.
3. Kosten TR, McCance E. A review of pharmacotherapies for substance abuse. Am J Addict. 1996;5:58-65.
4. O'Connor PG, Oliveto AH, Shi JM, Triffleman EC, Carroll KM, Kosten TR, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105:100-5.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Assoc; 1994.
6. Hamid A, Curtis R, McCoy K, McGuire J, Conde A, Bushell W, et al. The heroin epidemic in New York City: current status and prognoses. J Psychoactive Drugs. 1997;9:375-91.
7. Schottenfeld RS, O'Malley S, Abdul-Salaam K, O'Connor PG. Decline in intravenous drug use among treatment-seeking opiate users. J Subst Abuse Treat. 1993;10:5-10.
8. National Household Survey on Drug Abuse. Main Findings, 1997. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Services Administration; 1999.
9. Year-End Preliminary Estimates From the 1996 Drug Abuse Warning Network. Rockville, MD: Office of Applied Studies, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 1997.
10. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2d ed. Baltimore: Williams & Wilkins; 1996.
11. Stein MD. Medical complications of intravenous drug use. J Gen Intern Med. 1990;5:249-57.
12. Cherubin CE, Sapira JD. The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. Ann Intern Med. 1993;119:1017-28.
13. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection drug users with human immunodeficiency virus infection. N Engl J Med. 1994;331:450-9.
14. Sporer KA. Acute heroin overdose. Ann Intern Med. 1999;130:584-90.
15. Ziedonis D, Brady K. Dual diagnosis in primary care. Detecting and treating both the addiction and mental illness. Med Clin North Am. 1997; 81:1017-36.
16. Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71-80.
17. Darke S, Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend. 1997;48:135-41.
18. Chutuape MA, Brooner RK, Stitzer M. Sedative use disorders in opiate-dependent patients: association with psychiatric and other substance use disorders. J Nerv Ment Dis. 1997;185:289-97.
19. Warner EA, Kosten TR, O'Connor PG. Pharmacotherapy for opioid and cocaine abuse. Med Clin North Am. 1997;81:909-25.
20. Wyshak G, Modest GA. Violence, mental health, and substance abuse in patients who are seen in primary care settings. Arch Fam Med. 1996;5: 441-7.
21. Regidor E, Barrio G, de la Fuente L, Rodriguez C. Non-fatal injuries and the use of psychoactive drugs among young adults in Spain. Drug Alcohol Depend. 1996;40:249-59.
22. Liebschutz JM, Mulvey KP, Samet JH. Victimization among substance-abusing women. Worse health outcomes. Arch Intern Med. 1997; 157:1093-7.
23. Brewer DD, Fleming CB, Haggerty KP, Catalano RF. Drug use predictors of partner violence in opiate-dependent women. Violence Vict. 1998;13:107-15.
24. Prochaska JO, DiClemente CC, Velicer WF, Rossi JS. Criticisms and concerns of the transtheoretical model in light of recent research. Br J Addict. 1992;87:825-8; discussion 833-5.
25. Samet JH, Rollnick S, Barnes H. Beyond CAGE. A brief clinical approach after detection of substance abuse. Arch Intern Med. 1996;156: 2287-93.
26. Samet JH, O'Connor PG. Alcohol abusers in primary care: readiness to change behavior. Am J Med. 1998;105:302-6.
27. Friedmann PD, Saitz R, Samet JH. Management of adults recovering from alcohol or other drug problems: relapse prevention in primary care. JAMA. 1998;279:1227-31.
28. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav. 1990;15:487-90.
29. Fultz JM, Senay EC. Guidelines for the management of hospitalized narcotics addicts. Ann Intern Med. 1975;82:815-8.
30. Tennant FS Jr, Russell BA, Casas SK, Bleich RN. Heroin detoxification. A comparison of propoxyphene and methadone. JAMA. 1975;232: 1019-22.
31. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988;43:72-8.
32. Amass L, Bickel WK, Higgins ST, Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994;13:33-45.
33. Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend. 1994;36:115-21.
34. Nigam AK, Ray R, Tripathi BM. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat. 1993;10:391-4.
35. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend. 1988;21:253-9.
36. Charney DS, Sternberg DE, Kleber HD, Heninger CR, Redmond DE Jr. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry. 1981;38:1273-7.
37. Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Caspari J, et al. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry. 1985;42:391-4.
38. Rosen MI, McMahon TJ, Hameedi FA, Pearsall HR, Woods SW, Kreek MJ, et al. Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. J Pharmacol Exp Ther. 1996;276:1128-35.
39. O'Connor PG, Waugh ME, Carroll KM, Rounsaville BJ, Diagkogiannis IA, Schottenfeld RS. Primary care-based ambulatory opioid detoxification: the results of a clinical trial. J Gen Intern Med. 1995;10:255-60.
40. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med. 1997;127:526-30.
41. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol. 1998;92:854-8.
42. McCann MJ, Miotto K, Rawson RA, Huber A, Shoptaw S, Ling W. Outpatient non-opioid detoxification for opioid withdrawal. Who is likely to benefit? Am J Addict. 1997;6:218-23.
43. Beam J, Gossop M, Strang J. Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1996;43:87-91.
44. Kahn A, Mumford JP, Rogers GA, Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend. 1997;44:57-61.
45. Lin SK, Strang J, Su LW, Tsai CJ, Hu WH. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend. 1997;48:127-33.
46. Beam J, Gossop M, Strang J. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for inpatient opiate detoxification. Drug Alcohol Depend. 1998;50:227-32.
47. O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA. 1998;279:229-34.
48. Resnick RB, Kestenbaum RS, Washton A, Poole D. Naloxone-precipitated withdrawal: a method for rapid induction onto naltrexone. Clin Pharmacol Ther. 1977;21:409-13.
49. Chamey DS, Heninger GR, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry. 1986;143:831-7.
50. Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse. 1987;13:1-17.
51. Loimer N, Schmid R, Presslich O, Lenz K. Naloxone treatment for opiate withdrawal syndrome. Br J Psychiatry. 1988;153:851-2.
52. Scherbaum N, Klein S, Kaube H, Kienbaum P, Peters J, Gastpar M. Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification. Pharmacopsychiatry. 1998;31:205-9.
53. Rabinowitz J, Cohen H, Tarrasch R, Kotler M. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug Alcohol Depend. 1997;47:77-86.
54. Cucchia AT, Monnat M, Spagnoli J, Ferrero F, Bertschy G. Ultrarapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug Alcohol Depend. 1998;52:243-50.
55. San L, Puig M, Bulbena A, Farre M. High risk of ultrashort noninvasive opiate detoxification [Letter]. Am J Psychiatry. 1995;152:956.
56. Pfab R, Hirtl C, Zilker T. Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. J Toxicol Clin Toxicol. 1999;37:43-50.
57. Zielbauer P. State knew of risky heroin treatment before patient deaths. The New York Times. 31 October 1999:41.
58. Strang J, Beam J, Gossop M. Opiate detoxification under anaesthesia. BMJ. 1997;315:1249-50.
59. Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction? NIDA Res Monogr. 1995;150:37-52.
60. Kleber HD. Naltrexone. J Subst Abuse Treat. 1985;2:117-22.
61. Farren CK, O'Malley S, Rounsaville B. Naltrexone and opiate abuse. In: Stine SM, Kosten TR, eds. New Treatments for Opiate Dependence. New York: Guilford Pr; 1997:104-23.
62. Fram DH, Marmo J, Holden R. Naltrexone treatment - the problem of patient acceptance. J Subst Abuse Treat. 1989;6:119-22.
63. Kosten TR. Current pharmacotherapies for opioid dependence. Psychopharmacol Bull. 1990;26:69-74.
64. Greenstein RA, Arndt IC, McLellan AT, O'Brien CP, Evans B. Naltrexone: a clinical perspective. J Clin Psychiatry. 1984;45(9 Pt 2):25-8.
65. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry. 1978;35:335-40.
66. San L, Pomarol C, Peri JM, Olle JM, Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict. 1991;86:983-90.
67. Ling W, Wesson DR. Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience. J Clin Psychiatry. 1984;45(9 Pt 2):46-8.
68. Landabaso MA, Iraurgi I, Jimenez-Lerma JM, Sanz J, Fernandez De Corres B, Araluce K, et al. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts. Addiction. 1998;93: 739-44.
69. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science. 1997;278:58-63.
70. Nestler EJ. Basic neurobiology of opiate addiction. In: Stine SM, Kosten TR, eds. New Treatments for Opiate Dependence. New York: Guilford Pr; 1997:286.
71. Gilman AC, Goodman LS, Rall TW, Murad F, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 7th ed. New York: Macmillan; 1985.
72. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med. 1966;118:304-9.
73. Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence. A current perspective. West J Med. 1990;152:588-99.
74. Kreek MJ. Drug interactions with methadone in humans. NIDA Res Monogr. 1986;68:193-225.
75. Kreek MJ. Opiate-ethanol interactions: implications for the biological basis and treatment of combined addictive diseases. NIDA Res Monogr. 1988;81:428-39.
76. Iribame C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos. 1998;26:257-60.
77. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13:957-62.
78. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf. 1999;20:147-69.
79. Ebert B, Thorkildsen C, Andersen S, Criristrup LL, Hjeds H. Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Biochem Pharmacol. 1998;56:553-9.
80. Davis AM, Inturrisi CE. D-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther. 1999; 289:1048-53.
81. Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage. 1999;18:120-5.
82. Cooper JR. Including narcotic addiction treatment in an office-based practice. JAMA. 1995;273:1619-20.
83. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485-8.
84. Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend. 1981;7:249-56.
85. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcomes. New York: Springer-Verlag; 1991.
86. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA. 1965;193:646-50.
87. Newman RG. Methadone treatment. Defining and evaluating success. N Engl J Med. 1987;317:447-50.
88. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA. 1998;280:1936-43.
89. Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedman P, Trigg HL, et al. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991;81:1185-91.
90. Hubbard RL, Craddock SG, Flynn PM, Anderson J, Etheridge RM. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors. 1997;11: 261-78.
91. Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988;29:214-26.
92. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquit Immune Defic Syndr. 1993;6:1049-56.
93. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;113(Suppl 1):97-106.
94. Novick DM, Joseph H, Croxson TS, Salsitz EA, Wang G, Richman BL, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med. 1990;50:97-9.
95. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993;119:23-7.
96. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high- dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000-5.
97. Caplehom JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust. 1991;154:195-9.
98. Caplehom JR, Bell J, Kleinbaum DG, Gebski VJ. Methadone dose and heroin use during maintenance treatment. Addiction. 1993;88:119-24.
99. Cooper JR. Ineffective use of psychoactive drugs. Methadone treatment is no exception. JAMA. 1992;267:281-2.
100. D'Aunno T, Vaughn TE. Variations in methadone treatment practices. Results from a national study. JAMA. 1992;267:253-8.
101. Ward J, Mattick RP, Hall W. The use of urinalysis during opioid replacement therapy. In: Ward J, Mattick RP, Hall W, eds. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam: Harwood Academic Publishers; 1998:571.
102. Ling W, Compton P. Opiate maintenance therapy with LAAM. In: Stine SM, Kosten TR, eds. New Treatments for Opiate Dependence. New York: Guilford Pr; 1997:286.
103. Blaine JD. Early clinical studies of levo-alpha acetylmethadol (LAAM): an opiate for use in the medical treatment of chronic heroin dependence. NIDA Res Monogr. 1978(19):249-59.
104. Fraser HF, Isbell H. Actions and addiction liabilities of alpha-acetyl-methadols in man. J Pharmacol Exp Ther. 1952;105:458-65.
105. Jaffe JH, Senay EC, Schuster CR, Renault PR, Smith B, DiMenza S. Methadyl acetate vs methadone. A double-blind study in heroin users. JAMA. 1972;222:437-42.
106. Ling W, Charuvastra C, Kaim SC, Klett O. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study. Arch Gen Psychiatry. 1976;33:709-20.
107. Senay EC, Dorus W, Renault PF. Methadyl acetate and methadone. An open comparison. JAMA. 1977;237:138-42.
108. Freedman RR, Czertko G. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. Drug Alcohol Depend. 1981; 8:215-22.
109. Jaffe JH, Schuster CR, Smith BB, Blachley PH. Comparison of acetylmethadol and methadone in the treatment of long-term heroin users. A pilot study. JAMA. 1970;211:1834-6.
110. Ling W, Klett CJ, Gillis RD. A cooperative clinical study of methadyl acetate. I. Three-time-a-week regimen. Arch Gen Psychiatry. 1978;35:345-53.
111. Glanz M, Klawansky S, McAullife W, Chalmers T. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized, controlled trials. Am J Addict. 1997;6:339-49.
112. Eissenberg T, Bigelow GE, Strain EC, Walsh SL, Brooner RK, Stitzer ML, et al. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial. JAMA. 1997;277: 1945-51.
113. Oliveto AH, Farren C, Kosten TR. Effect of LAAM dose on opiate use in opioid-dependent patients. A pilot study. Am J Addict. 1998;7:272-82.
114. Rawson RA, Hasson AL, Huber AM, McCann AAJ, Ling W. A 3-year progress report on the implementation of LAAM in the United States. Addiction. 1998;93:533-40.
115. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475-86.
116. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine. A potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978;35:501-16.
117. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569-80.
118. Jasinski DR, Fudala PJ, Johnson RE. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther. 1989;45:513-9.
119. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol. 1998;22: 430-4.
120. Iribarne C, Picart D, Dreano Y, Berthou F. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol. 1998;12:194-9.
121. Mello NK, Mendelson JH, Kuehnle JC. Buprenorphine effects on human heroin self-administration: an operant analysis. J Pharmacol Exp Ther. 1982;223:30-9.
122. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 1995;40:17-25.
123. Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther. 1990;47:525-34.
124. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci. 1994;54: 1215-28.
125. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend. 1995;40:27-35.
126. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-5.
127. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53:401-7.
128. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl). 1994;116:401-6.
129. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis. 1993;181:358-64.
130. Carroll KM, Schottenfeld R. Nonpharmacologic approaches to substance abuse treatment. Med Clin North Am. 1997;81:927-44.
131. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993; 269:1953-9.
132. Kraft KM, Rothbard AB, Hadley TR, McLellan AT, Asch DA. Are supplementary services provided during methadone maintenance really cost-effective? Am J Psychiatry. 1997;154:1214-9.
133. Payte JT, Khuri ET. Treatment duration and patient retention. Center for Substance Abuse Treatment. Rockville, MD: U.S. Department of Health and Human Services; 1993. Report no. 93-1991.
134. Fleming MF, Barry KL, Manwell LB, Johnson K, London R. Brief physician advice for problem alcohol drinkers. A randomized controlled trial in community-based primary care practices. JAMA. 1997;277:1039-45.
135. Novick DM, Pascarelli EF, Joseph H, Salsitz EA, Richman BL, Des Jarlais DC, et al. Methadone maintenance patients in general medical practice. A preliminary report. JAMA. 1988;259:3299-302.
136. Novick DM, Joseph H, Salsitz EA, Kalin MF, Keefe JB, Miller EL, et al. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J Gen Intern Med. 1994;9: 127-30.
137. Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA. 1988;260:3025-9.
138. Senay EC, Barthwell AG, Marks R, Bokos P, Gillman D, White R. Medical maintenance: a pilot study. J Addict Dis. 1993;12:59-76.
139. Parrino MW. The tornado of change. Journal of Maintenance in the Addictions. 1998;1:71-80.
140. State Methadone Treatment Guidelines. v 1. Rockville: U.S. Department of Health and Human Services; 1993.